Hookipa Biotech to Present New Phase 1 Data for its Cytomegalovirus Vaccine, HB-101 at the World Vaccine Congress

  • Vaccine has a good safety profile and elicits strong humoral and cellular immune responses beyond twelve months.

Vienna, Austria, 27 March 2018 - Hookipa Biotech AG (“Hookipa”), a clinical stage biotech company pioneering an innovative class of active immunization therapies for oncology and infectious diseases, will present new data from a Phase 1 trial of HB-101, a vaccine against human cytomegalovirus (CMV).

The data will be presented at the World Vaccine Congress by Dr. Camille Kotton, Clinical Director of Transplant and Immunocompromised Host Infectious Diseases at the Massachusetts General Hospital. Full details of the oral presentation are below:

Presentation title: A CMV Vaccine Based on Non-Replicating Lymphocytic Choriomeningitis Virus Vectors Expressing gB and pp65: 12 months Phase 1 data supporting a Phase 2 Randomized, Placebo-Controlled Trial in CMV-Negative Recipient Patients Awaiting Kidney Transplantation from CMV-Positive Donors.
Time and date: 12:40pm – EDT, Wednesday, 4 April
Location: Ballroom, Renaissance Washington DC Downtown Hotel

The new data provide further evidence that the vaccine is safe, well tolerated, and elicits strong humoral and cellular immune responses. Long-term follow-up data presented at the conference confirms that immune responses are maintained beyond twelve months.


About Hookipa Biotech

Hookipa Biotech is a clinical stage company developing next-generation immunotherapies for
infectious diseases and cancer using novel proprietary arenavirus vector platforms.

Hookipa´s Vaxwave® technology presents a completely new replication-defective viral vector
platform designed to overcome the limitations of current technologies. Vaxwave® is based on
lymphocytic choriomeningitis virus (LCMV). In this vector the gene encoding the LCMV
envelope protein, normally responsible for virus entry into target cells, has been deleted and
replaced with an antigen of interest. The resulting vectors infect dendritic cells and stimulate
very potent and long-lasting immune response, however they cannot replicate and are therefore
non-pathogenic and inherently safe.

Hookipa’s TheraT® platform is based on an attenuated replicating arenavirus and is capable of
eliciting the most potent T cell responses - a crucial step in treating patients with aggressive
cancers. Significant pre-clinical data demonstrates that TheraT® is a powerful modality capable
of turning “cold tumors hot” which should result in an additional layer of efficacy in the fight
against solid tumors. Specifically, TheraT® has proven to be safe in animals as well as capable
of eliciting uniquely potent antigen-specific CD8+ cytotoxic T cell responses and strong tumor
control in mice. The first clinical trial with HB-201 targeting human papilloma virus-induced
head and neck cancer is currently being prepared. This immuno-oncology technology is further
being leveraged to target tumor self-antigens or shared neoantigens.

Find out more about Hookipa on the company website at hookipabiotech.com.

Issued for and on behalf of Hookipa Biotech AG by Instinctif Partners. For further information
please contact:

At the Company
Marine Popoff
Communications Analyst
Hookipa Biotech AG

Media enquiries
Sue Charles/ Ashley Tapp
Instinctif Partners
+44 (0)20 7866 7905